Carlo; Dennis J.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Carlo; Dennis J..The latest application filed is for "formulation including a combination of beta-endorphin and adrenocorticotropic hormone".
Company Profile
5.25.18
- Carlo; Dennis J. - San Diego CA
- Carlo; Dennis J - Rancho Santa Fe CA
- Carlo, Dennis J. - Rancho Santa Fe CA
- Carlo; Dennis J. - Bound Brook NJ
- Carlo; Dennis J. - South Amboy NJ
- Carlo; Dennis J. - Middlesex NJ
- Carlo; Dennis J. - Middlessex NJ
- Carlo; Dennis J. - Rahway NJ
Patent Activity
| Patent | Date |
|---|---|
| Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone App 20220241381 - Lollo; Charles Peter ; et al. | 2022-08-04 |
| Formulation including a combination of beta-endorphin and adrenocorticotropic hormone Grant 11,285,192 - Lollo , et al. March 29, 2 | 2022-03-29 |
| Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone App 20220054595 - Lollo; Charles Peter ; et al. | 2022-02-24 |
| Drug Compositions App 20220000876 - Sutherland; David Clayton ; et al. | 2022-01-06 |
| Emergency Devices App 20210290857 - Flather; Mark J. ; et al. | 2021-09-23 |
| Drug Compositions App 20210267945 - Sutherland; David Clayton ; et al. | 2021-09-02 |
| Drug Compositions App 20210205270 - Sutherland; David Clayton ; et al. | 2021-07-08 |
| Drug compositions Grant 11,045,450 - Sutherland , et al. June 29, 2 | 2021-06-29 |
| Emergency devices Grant 11,027,072 - Flather , et al. June 8, 2 | 2021-06-08 |
| Formulation Including a Combination of beta-Endorphin and Adrenocorticotropic Hormone App 20210100878 - Lollo; Charles Peter ; et al. | 2021-04-08 |
| Drug Compositions App 20200138823 - Sutherland; David Clayton ; et al. | 2020-05-07 |
| Emergency Devices App 20200121859 - Flather; Mark J. ; et al. | 2020-04-23 |
| Drug Compositions App 20190388396 - Sutherland; David Clayton ; et al. | 2019-12-26 |
| Drug Compositions App 20190358209 - Carlo; Dennis J. | 2019-11-28 |
| Drug compositions Grant 10,441,575 - Sutherland , et al. Oc | 2019-10-15 |
| Drug compositions comprising an anti-parasitic and proton pump inhibitor Grant 10,137,111 - Sutherland , et al. November 27, 2 | 2018-11-27 |
| Drug Compositions App 20180333358 - Carlo; Dennis J. | 2018-11-22 |
| Drug Compositions App 20180193316 - Sutherland; David Clayton ; et al. | 2018-07-12 |
| Drug Compositions Comprising An Anti-parasitic And Proton Pump Inhibitor App 20180042901 - Sutherland; David Clayton ; et al. | 2018-02-15 |
| Method for increasing HDL cholesterol level Grant 7,074,407 - Kwoh , et al. July 11, 2 | 2006-07-11 |
| Compositions as adjuvants to improve immune responses to vaccines and methods of use App 20050276756 - Hoo, William Soo ; et al. | 2005-12-15 |
| Targeted delivery of genes encoding interferon App 20040002466 - Chiou, Henry C. ; et al. | 2004-01-01 |
| Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment App 20030044428 - Moss, Ronald B. ; et al. | 2003-03-06 |
| Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations Grant 6,464,978 - Brostoff , et al. October 15, 2 | 2002-10-15 |
| Genetically engineered tumor cell vaccines App 20020006413 - Sobol, Robert E. ; et al. | 2002-01-17 |
| Method of preventing the proliferation of V.beta.14 or V.beta.17-Expressing T cells Grant 6,221,352 - Howell , et al. April 24, 2 | 2001-04-24 |
| Vaccination and methods against diseases resulting from pathogenic responses Grant 6,090,387 - Howell , et al. July 18, 2 | 2000-07-18 |
| Targeted delivery of genes encoding interferon Grant 6,069,133 - Chiou , et al. May 30, 2 | 2000-05-30 |
| Prevention and treatment of retroviral disease Grant 6,017,543 - Salk , et al. January 25, 2 | 2000-01-25 |
| Prevention and treatment of retroviral disease Grant 5,928,930 - Salk , et al. July 27, 1 | 1999-07-27 |
| Prevention and treatment of retroviral disease Grant 5,916,806 - Salk , et al. June 29, 1 | 1999-06-29 |
| Prevention and treatment of retroviral disease Grant 5,885,578 - Salk , et al. March 23, 1 | 1999-03-23 |
| Prevention and treatment of retroviral disease Grant 5,853,725 - Salk , et al. December 29, 1 | 1998-12-29 |
| Vaccination against diseases resulting from pathogenic responses by specific T cell populations Grant 5,612,035 - Howell , et al. March 18, 1 | 1997-03-18 |
| Retroviral antigens Grant 5,256,767 - Salk , et al. October 26, 1 | 1993-10-26 |
| Group B streptococcal capsular polysaccharides Grant 4,413,057 - Carlo , et al. November 1, 1 | 1983-11-01 |
| Antigenic complex from N. gonorrhoeae Grant 4,288,557 - Karkhanis , et al. September 8, 1 | 1981-09-08 |
| Vaccine for dental caries Grant 4,287,173 - Carlo , et al. September 1, 1 | 1981-09-01 |
| Meningitis vaccine Grant 4,264,764 - Kniskern , et al. April 28, 1 | 1981-04-28 |
| Antigenic complex from N. Gonorrhoeae Grant 4,220,638 - Karkhanis , et al. September 2, 1 | 1980-09-02 |
| E. coli enterotoxin vaccine for veterinary and human use Grant 4,220,584 - Limjuco , et al. September 2, 1 | 1980-09-02 |
| Swine atropic rhinitis vaccine Grant 4,203,970 - Carlo , et al. May 20, 1 | 1980-05-20 |
| Method for preparing high molecular weight meningococcal Group C vaccine Grant 4,123,520 - Hagopian , et al. October 31, 1 | 1978-10-31 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 